Navigation Links
Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Date:8/13/2012

CARLSBAD, Calif., Aug. 13, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has delivered a notice of redemption relating to all of its outstanding 2 ⅝% Convertible Subordinated Notes due 2027 (the "2027 Notes") at a redemption price of 100.75% of the principal amount thereof.  As of August 13, 2012, $162,500,000 aggregate principal amount of the 2027 Notes was outstanding.  The 2027 Notes will be redeemed on September 12, 2012 unless earlier converted.  The CUSIP Numbers of the 2027 Notes are 464337AD6 and 464337AE4.

The 2027 Notes are convertible at any time prior to 5:00 p.m. Eastern Time, September 11, 2012 at a rate of 68.3761 shares of common stock per $1,000 principal amount of the 2027 Notes converted.  If any 2027 Notes are surrendered for conversion, the conversion will be settled in cash.

Wells Fargo Bank, N.A., the trustee for the 2027 Notes, is delivering a Notice of Redemption to all registered holders of the 2027 Notes on August 13, 2012.  Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2027 Notes may be obtained from the Wells Fargo Bank, N.A., by calling (800) 344-5128.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
2. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
3. Intercept Pharmaceuticals Closes $30 Million Series C Financing
4. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
5. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
7. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
8. Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
10. Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
11. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Columbia Laboratories, Inc. (Nasdaq: ... today announced financial results for the three and ... "Second quarter results benefited from the contribution ... diversified revenue stream partially offset an anticipated and ... during a routine license renewal in one high-volume, ...
(Date:7/31/2014)... 31, 2014 Marken announced today the expansion ... meet the clinical trial logistics growth in Central and ... facility will continue to serve as a regional center ... from the region, and will provide additional storage capacity. ... combine its office and warehouse into a single facility, ...
(Date:7/31/2014)... , July 31, 2014 ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... Report. Diabetes, growing at an exponential rate ... has emerged as a major cause of death of ...
Breaking Medicine Technology:Columbia Laboratories Reports Second Quarter 2014 Financial Results 2Columbia Laboratories Reports Second Quarter 2014 Financial Results 3Columbia Laboratories Reports Second Quarter 2014 Financial Results 4Columbia Laboratories Reports Second Quarter 2014 Financial Results 5Columbia Laboratories Reports Second Quarter 2014 Financial Results 6Columbia Laboratories Reports Second Quarter 2014 Financial Results 7Columbia Laboratories Reports Second Quarter 2014 Financial Results 8Columbia Laboratories Reports Second Quarter 2014 Financial Results 9Columbia Laboratories Reports Second Quarter 2014 Financial Results 10Columbia Laboratories Reports Second Quarter 2014 Financial Results 11Columbia Laboratories Reports Second Quarter 2014 Financial Results 12Marken Expands Miami Regional Logistics Center 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 3The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 4The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 5The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 6The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 7The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 8
... Electronics, Inc. (NYSE: BHE ), a leading ... it helped commercialize and currently manufactures has won the ... for best new science and medical diagnostic product. ... 2011 Medical Design Excellence Award in the In Vitro ...
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... and CEO will deliver a corporate presentation on Thursday, ... The presentation will take place as part of the ...
Cached Medicine Technology:Benchmark Electronics Recognized as Supplier for 2011 Design Medical Excellence Award Winner 2
(Date:7/31/2014)... bill introduced in Congress with bipartisan support would allow ... Michigan research, which could improve the health of patients ... the medicines and tests they need most. , The ... and Earl Blumenauer, grew out of a decade of ... Institute for Healthcare Policy and Innovation. It would allow ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of cancer ... Heat-Shock Factor 1 (HSF1) can also turn neighboring ... malignant progression and metastasis. , The finding, reported ... journal Cell , lends new insights into ... prognosis, and management of cancer patients. , ...
(Date:7/31/2014)... 31, 2014 The North America Phytochemicals & ... plant extracts market in North America with analysis and forecast ... around $576.3 million in 2012 to $930.1 million by 2018, ... Browse through the TOC of the North America phytochemicals & ... in-depth analysis provided. It also provides a glimpse of the ...
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 ... publication dedicated to delivering cutting-edge information focused ... and therapeutics, recently launched its newly designed ... website optimizes navigation by providing visitors specialized ... analytical and strategic business areas. As the ...
Breaking Medicine News(10 mins):Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:BioProcess International Launches New Website 2
... and observational studies show an increased risk for cancer ... problem may be worse than currently known. ... going to see the current disparity in knowledge and ... director of the Institute for Health Promotion Research at ...
... Researchers at the University of Alabama at Birmingham ... four biomarkers that will help predict which patients are ... are not. The findings also shed light on the ... African-Americans, compared with Caucasians, the researchers said. In ...
... John Theurer Cancer Center at Hackensack University Medical Center ... patients on Friday, April 23 and Saturday, April 24. ... Management of Hematological Malignancies", is part of John Theurer ... well as patients with an update on the newest ...
... heart problems that stems from a genetic defect in the ... protein,s function can lead to cardiac arrest, which is exactly ... investigation at Sahlgrenska University Hospital at the University of Gothenburg, ... today in the revered New England Journal of Medicine ...
... ... release of their new title in the Tarascon Pocketbook series, Tarascon Global Health Pocketbook, ... portable guide provides regional and issue-based information on international medicine throughout the world. ... Sudbury, MA (Vocus) ...
... Study found infection rates highest among black children in ... -- Treatment-resistant ringworm is common among urban elementary school ... in kindergarten through Grade 5 at 44 schools across ... 6.6 percent of them were infected with the fungus ...
Cached Medicine News:Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 2Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 3Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 4Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 5Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 6Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 7Health News:UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis 2Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 2Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 3Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 4Health News:New explanation for cardiac arrest 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 3Health News:Resistant Ringworm Common in Urban Elementary Schools 2
... Implants are comprised only of synthetic, medical ... designed to support soft tissue ingrowth. Ocu-pore ... sizes. The material is manufactured using a ... produce a highly porous, fully interconnected, biocompatible ...
Straight iris forceps. Insulated....
Bayonet forceps....
Semkin forceps with stops. Insulated....
Medicine Products: